1. Viscosupplementation for Osteoarthritis of the Knee: A Key Opinion Leader Panel Discussion.
- Author
-
Bert J, Kenney J, Sgaglione NA, McClelland S, Brophy R, Toth J, Ruane J, Ali Y, Arquette S, Dasa V, and Lopes M
- Subjects
- Attitude, Cost of Illness, Cost-Benefit Analysis, Humans, Osteoarthritis, Knee diagnosis, Osteoarthritis, Knee economics, Osteoarthritis, Knee epidemiology, Practice Guidelines as Topic, Prevalence, Professional Practice Gaps, Quality of Life, Treatment Outcome, United States epidemiology, Viscosupplementation standards, Hyaluronic Acid therapeutic use, Osteoarthritis, Knee drug therapy, Viscosupplementation methods
- Abstract
With a sharp rise in the prevalence of osteoarthritis of the knee (OAK) in a younger population, new management strategies are needed to preserve mobility, improve patients' quality of life, and reduce the effects of potential disease-related comorbidities. Viscosupplementation with the use of hyaluronic acid (HA) injection is a treatment option for OAK that can provide lubrication and elastic shock absorption, leading to potential pain relief, improved function, and reduced stiffness. A key opinion leader (KOL) panel discussion was held December 3, 2016, with the objective of sharing opinions, ideas, information, and trends regarding OAK and the potential treatment and management offered by viscosupplementation. The panel concluded that viscosupplementation with HA injections presents a viable, cost-effective, and safe alternative for the treatment of OAK., Disclosures: This panel discussion and report was facilitated by Magellan Rx Manage-ment and funded by Sanofi. Bert and Ruane report fees from Sanofi outside of this project. Sgaglione reports royalty payments from Zimmer Biomet and Wolters Kluwer. Dasa has received fees from Bioventus and Myoscience. All the authors received an honorarium for work on this project. Lopes is employed by Magellan Rx Management.
- Published
- 2018
- Full Text
- View/download PDF